CARTUCHOS DE TESTE PERSONALIZÁVEIS E CAIXA LEITORA PARA ENSAIOS DE AMPLIFICAÇÃO DE ÁCIDO NUCLEICO
The customizable test cartridge and reader box system addresses the impracticality and cost of NAA tests by allowing on-site assembly and use, enhancing accessibility and accuracy of NAA tests beyond traditional laboratories.
Patent Information
- Application Number
- BR112025024372
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-09
- Publication Date
- 2026-11-10
AI Technical Summary
Nucleic acid amplification tests (NAA) are impractical and expensive to perform outside traditional laboratory settings due to the need for complex equipment and specialized skills, limiting their widespread use.
A customizable test cartridge with fluidic chambers and a reader box that allows for on-site assembly and use of reagents, enabling NAA tests to be performed in non-laboratory settings.
Enables convenient, cost-effective, and accurate NAA testing outside laboratories, facilitating broader access and use of NAA tests.
Abstract
Description
1 / 19 “CUSTOMIZABLE TEST CARTRIDGES AND READER BOX FOR NUCLEIC ACID AMPLIFICATION ASSAYS” Cross-reference to related orders
[001] This application claims the benefit of priority under 35 USC §119(e) of U.S. Provisional Application No. 63 / 466,099, filed May 12, 2023. The disclosure of the prior application is considered part of, and is incorporated herein by reference in the disclosure of this application in its entirety. Field of Invention
[002] This disclosure relates to customizable test cartridges and a reader box for Nucleic Acid Amplification (NAA) assays. Background
[003] The NAA test is a widely used technique for detecting genetic material from a variety of sources. For example, the NAA test is used on a biological specimen, such as a nasal cavity or throat swab, to detect whether genetic material from a pathogen is present. The recent COVID-19 pandemic highlighted the importance of the diagnostic NAA test, which is known to be significantly reliable compared to rapid antigen tests (test kits commonly available at home that show a positive result only when there is a detectable level of antigen / antibody).
[004] Due to their complexity, NAA tests have traditionally been performed in laboratory facilities. In other words, a patient visits a doctor's office or laboratory to provide the biological sample, which is processed by complex and expensive machines. Processing typically involves polymerase chain reaction (PCR) reactions to generate millions (and even billions) of copies of the target sequence for optimal detection. These processes require complex equipment and specialized training.
[005] Unlike rapid antigen tests, NAA tests have been Petition 870250102292, dated 07 / 11 / 2025, p. 16 / 44 2 / 19 impractical and prohibitively expensive to perform in a facility outside of a traditional laboratory. For example, sample collection and amplification equipment involves a complex array of machines, test tubes, and reagents, and also requires specific technical skills. Therefore, while more accurate in terms of diagnosis, NAA tests have remained confined to laboratories and clinical facilities, such as hospitals, and are not readily available for more widespread use by patients.
[006] Thus, a significant improvement in NAA testing, particularly to support testing outside the traditional laboratory setting, is therefore desirable. Brief Description of the Invention
[007] The embodiments described in this document solve the problems mentioned above and may also provide other solutions. In one embodiment, a customizable test cartridge and a reader box are provided. The test cartridge may have multiple fluidic chambers connected by fluidic tubing; the fluidic chambers are used to perform different parts of the NAA test. The test cartridge has external interfaces, for example, a snap-in feature, for a user and / or the reader box to insert a chemical reagent and / or a reaction chamber. The reader box has dispensing structures, for example, a spring-loaded dispenser (e.g., a Pez-type dispenser) or a rotary dispenser (a contraceptive pill-type dispenser) to dispense the chemical reagents into the test cartridge. This flexibility allows the test cartridges to be manufactured as empty and the reagents to be added in situ for testing.In some versions, test cartridges can be manufactured with only primers and probes, and other reagents can be added by the user and / or the reader box during the test. Therefore, the cartridges can be easily manufactured, are generally cheaper, and... Petition 870250102292, dated 07 / 11 / 2025, page 17 / 44 3 / 19 significantly more convenient compared to existing NAA testing equipment.
[008] In one embodiment, a system for nucleic acid amplification testing is provided. The system may include a customizable test cartridge comprising a plurality of fluidic chambers interconnected by fluidic tubing, the customizable test cartridge with a primer and a probe, and configured to receive a sample to be tested. The system may also include a reader box configured to: receive the customizable test cartridge, insert an enzyme or other applicable reagents into the customizable test cartridge, and generate a nucleic acid amplification test result on the sample.
[009] In another embodiment, a customizable cartridge for nucleic acid amplification testing is provided. The customizable cartridge may include a plurality of fluidic chambers interconnected by fluidic tubing, the customizable test cartridge with a primer and a probe for nucleic acid amplification testing in one of the pluralities of fluidic chambers.
[010] In another embodiment, a nucleic acid amplification test method is provided. The method may include insertion, into a reader box, of a customizable test cartridge comprising a plurality of fluidic chambers interconnected by fluidic tubing, the customizable test cartridge with a primer and a probe, and a sample to be tested. The method may further include insertion, by the reader box, of an enzyme or other reagents applicable to the customizable test cartridge. The method may also include generation, by the reader box, of a nucleic acid amplification test result on the sample. Brief Description of the Figures
[011] FIGURE 1 represents an example test environment, based on the example modalities of this disclosure. Petition 870250102292, dated 07 / 11 / 2025, page 18 / 44 4 / 19
[012] FIGURE 2A represents a cross-section of an example customizable test cartridge, according to example embodiments of this disclosure.
[013] FIGURE 2B represents a cross-section of another example customizable test cartridge, according to example embodiments of this disclosure.
[014] FIGURE 3 shows an example rotary dispenser for dispensing a reagent into the test cartridge, according to example embodiments of the present disclosure.
[015] FIGURE 4 shows an example spring-loaded dispenser for dispensing a reagent into the test cartridge, according to example embodiments of the present disclosure.
[016] FIGURES 5A-5B show an example attachment in the test cartridge, according to example embodiments of this disclosure.
[017] It should be understood that the Figures above are for illustrative purposes only and should therefore not be considered limiting. Detailed Description of the Invention
[018] FIGURE 1 represents an example test environment 100, based on the example embodiments of this disclosure. As shown, the example test environment 100 includes a reader box 102 and a customizable test cartridge 120. However, it should be understood that the example test environment 100 — with the reader box 102 and the test cartridge 120 — is for illustration purposes only and should not be considered limiting. Alternative test environments with alternative, additional, or fewer components should be considered within the scope of this disclosure.
[019] The reader box 102, shown in a perspective view in FIGURE 1, is configured to receive the test cartridge 120 to perform an NAA test. Petition 870250102292, dated 07 / 11 / 2025, page 19 / 44 5 / 19 in the sample inside test cartridge 120. For this purpose, reader box 102 has one or more cartridge ports 104a and 104b (commonly referred to as a cartridge port 104 and collectively referred to as cartridge ports 104). In this example, two cartridge ports 104a and 104b are shown, where each cartridge port 104a and 104b is configured to receive its own cartridge. In other examples, however, reader box 102 may include a single cartridge port 104 or multiple cartridge ports 104, so any number of cartridge ports 104 inside reader box 102 should be considered within the scope of this disclosure.
[020] The reader box 102 additionally includes a tray 106 configured to receive bulk reagents for NAA testing. Bulk reagents may include, for example, but not limited to, primers, probes, and / or any other chemical reagents used for NAA testing. Other chemical reagents may include, among others, enzymes and salts. In some embodiments, the tray 106 is configured to slide out of the reader box 102 to load the bulk reagents. These bulk reagents are introduced into the test cartridge 120 when loaded into the reader box 102. For example, a set of microfluidic pumps within the reader box 102 may transport the bulk reagents from the tray 106 to the test cartridge 102. Additionally or alternatively, the reader box 102 may include a port 108 for inserting a rotary dispenser (e.g., a contraceptive pill-type dispenser).Port 108 may include any type of attachment and / or connection mechanism to the rotary dispenser. For example, port 108 may include a circular opening to receive the rotary dispenser, a spring-loaded mechanism to hold the rotary dispenser under mechanical tension and to move the rotary dispenser one step after an enzyme is dispensed. Reader box 102 may also include another port 110 for inserting a spring-loaded dispenser. Each of the rotary dispensers and spring-loaded dispensers. Petition 870250102292, dated 07 / 11 / 2025, page 20 / 44 6 / 19 is configured to dispense a pellet, powder or lyophilized material, or similar, of a chemical substance (e.g., enzyme) onto test cartridge 120 when it is inserted into reader box 102.
[021] The reader box 102 additionally includes an eject button 112 for removing one or more inserted test cartridges (e.g., test cartridge 120). Generally, the eject button 112 disengages an electromechanical mechanism that engages the test cartridge 120 to the reader box 102, thus allowing the safe removal of the test cartridge 120 from the reader box 102.
[022] The reader box 102 includes additional electronic components (not shown). For example, the reader box 102 may include a processor, such as, without limitation, a microprocessor and / or a controller to control the overall functionality of the reader box 102. The reader box 102 may additionally include communication components, such as, without limitation, a Bluetooth / Wi-Fi chip, so that the reader box 102 can communicate with other devices, for example, a nearby smartphone or a remote server. Therefore, any form of hardware and software architecture configured to provide communication and processing functionality should be considered within the scope of this disclosure.
[023] The reader box 102 also includes reading / testing components. For example, the reader box 102 may include a Fluorescence plate reader and / or any other similar reader components.
[024] Test cartridge 120 may include fluidic chambers and fluidic channels between them (discussed in detail below). The fluidic chambers are configured to receive biological samples and / or reagents used for NAA testing. Test cartridge 102 may also include one or more interfaces 122 to receive biological samples and / or the reagents (also discussed in detail below).
[025] In a non-limiting example of an operation, a patient provides a biological sample, including, without limitation, a nasal, oral or throat swab, to Petition 870250102292, dated 07 / 11 / 2025, page 21 / 44 7 / 19 test cartridge 120 is loaded into a cartridge port 104 of the reader box 102. The reader box is pre-loaded with bulk reagents, for example, without limitation, using tray 106; and with other reagents in pellets, powder, lyophilized material or comparable form, for example, without limitation, through one or more of ports 108 and 110. Alternatively, an operator (who may or may not be the patient) may attach one or more reagents or reaction chambers to the test cartridge 120 before loading it into the reader box 102. The reader box 102, in turn, uses the reagents from the biological sample to perform the various steps of the NAA test. The test results can then be provided to a smartphone and / or a remote server for internet access.
[026] FIGURE 2A represents a cross-section of the example test cartridge 120, according to the example embodiments of this disclosure. It should be understood that the cross-section shown is merely an illustration and should not be considered limiting. In other words, cartridges with different cross-sections, with additional, alternative or fewer components, should be considered within the scope of this disclosure. Additionally, the structure of the test cartridge 120 is described in terms of its functionality for ease of understanding, and the described structure-functionality coupling should not be considered limiting.
[027] Test cartridge 120 includes a sample collection vial 202 with a cap 204. The cap 204 can be made of any type of material, such as plastic. The sample collection vial 202 is configured to receive the biological sample that will be amplified by NAA and then tested. The biological sample is provided by a patient and, in some embodiments, this is all that is required from the patient, and the reader box 102 can operate all reagents. The biological sample may include, for example, without limitation, sputum, saliva, blood, serum, urine, mucus, skin cells, tissue, nasal or throat swab, fecal matter and / or any type Petition 870250102292, dated 07 / 11 / 2025, page 22 / 44 8 / 19 of biological sample. The biological sample may be introduced into the sample collection vial 202 by means of any type of mechanism, such as, without limitation, a swab tip, a blood collection stick and / or any other type of mechanism. For example, skin cells may be scraped off or added to the test cartridge 120. The sample collection vial 202 may also include a mechanism to determine the adequacy of the biological sample. For example, the sample collection vial 202 may include a line to which the biological sample should be filled. The reader box 102 may include a complementary mechanism (e.g., an optical reader) to determine and indicate the presence of an adequate amount of biological sample. A sample buffer port 206 is configured to receive a sample buffer to maintain a stable pH environment for the sample.
[028] A lysis chamber 208 is formed within the test cartridge 120. The sample in the sample collection vial 202 can be moved into the lysis chamber 208 by means of any type of mechanism, such as, without limitation, capillary action, gravity, pressure applied by the reader box 102, for example, using the sample buffer. The lysis chamber 208 may have multiple ports to receive various reagents and / or components necessary for the NAA test from the reader box 102. For example, port 210 receives Guanidine Hydrochloride (HCl) to be added to the sample. Port 212 receives isopropyl alcohol and magnetic beads from the reader box 102. Port 214 receives a washing buffer from the reader box 102.
[029] After all 210, 212, and 214 have received their corresponding reagents and components, the mixture in lysis chamber 208 is heated, for example, heated for 2 minutes at 90 degrees Celsius. The heating can be carried out by the reader box 102 by means of any type of mechanism. For example, the reader box 102 may have a resistive heating wire that is close to lysis chamber 208 to provide the necessary amount of heat. After the mixture is Petition 870250102292, dated 07 / 11 / 2025, p. 23 / 44 9 / 19 heated, the reader box 102 can activate its magnets (e.g., electromagnets) to pull the magnetic spheres to one side of the lysis chamber 208. The residues are then pushed into the residue area 216. The reader box 102 can add the washing buffer (i.e., through port 214) and push the residues into the residue area 216 for a few more cycles. After the washing cycles are completed, the suspension in the lysis chamber 208 is moved to an elution chamber 218 using the magnetic spheres (e.g., by means of electromagnets).
[030] In the elution chamber 218 formed within the test cartridge 120, the magnetic beads can be pushed away and the residue can be pushed into the residue area 216. The magnetic beads are then released back into the elution chamber. The reader box 102 adds an elution buffer, via port 220, to the elution chamber 218. After the addition of the elution buffer, the magnetic beads are pushed away again and the mixture is pushed into chamber 222.
[031] Inside chamber 222, an enzyme pellet is added to the mixture via a dispenser. In some embodiments, the dispenser may include a spring-loaded Pez-type dispenser that adds an enzyme pellet to chamber 222. In some embodiments, the dispenser may include a rotary dispenser, for example, without limitation, a contraceptive-type dispenser, which adds one or more enzyme pellets and / or other reagents to the chamber.
[032] The mixture is then pushed into chambers 224 and 226, where primers and probes, for example, lyophilized ones, can be pre-loaded. For example, chamber 226 may have primers and probes for one pathogen and chamber 224 may have primers and probes for another pathogen. In these chambers 224 and 226, an isothermal amplification can be initiated at 60 degrees Celsius. As an example, a fluorescent detection can be performed at this temperature in the green, red and any other spectrum.
[033] However, it must be understood that pre-loaded primers and Petition 870250102292, dated 07 / 11 / 2025, p. 24 / 44 10 / 19 probes in chambers 224 and 226 are optional; for example, these chambers may be empty during manufacturing. All reagents may be added via the reader box 102 or by the user. Essentially, test cartridge 120 can be manufactured as a blank piece to be quickly customizable during use. Optionally, chambers 224 and 226 themselves may be optional, and an alternative test cartridge may be manufactured without chambers 224 and 226. For example, FIGURE 2B depicts a cross-section of another example test cartridge 121, according to example embodiments of this disclosure. In particular, the example test cartridge 121 may not have chambers 224 and 226 for primers and probes. Primers and probes may be added directly, for example, by fitting into attachments, as described below with reference to FIGURES 5A-5B.The attachments, in turn, can provide the functionality of cameras 224 and 226 shown in FIGURE 2A.
[034] FIGURE 3 shows an example rotary dispenser 302 for dispensing a reagent into the test cartridge 120, according to example embodiments of the present disclosure. The rotary dispenser 302 and its interface with the test cartridge 120 are for illustrative purposes only and should not be considered limiting.
[035] As shown, the rotary dispenser 302 is divided into multiple chambers 314. Each chamber 314 may contain a single piece of a dry or lyophilized reagent 312 (e.g., an enzyme pellet). The rotary dispenser 302 may be loaded into the reader box 102 via port 108. The rotary dispenser 302 may be rotated (as shown, clockwise) using a motorized mechanism in the reader box 102. Rotation generally causes a chamber of the rotary dispenser 302 to interface with a port 310 of the test cartridge 120. The chamber interfacing with port 310 may have any type of opening mechanism 304 that allows the dry or lyophilized reagent 312 stored in the Petition 870250102292, dated 07 / 11 / 2025, page 25 / 44 11 / 19 itself moves away from the chamber. For example, the opening mechanism 304 may be a swinging door, which can open due to gravity and the dry or lyophilized reagent 312 move to the door 310 through the action of gravity itself. In other embodiments, the reader box 102 may have an equivalent mechanical / electromechanical part that engages the opening mechanism 304, which allows the dry or lyophilized reagent 312 to move downwards due to the action of gravity. In other embodiments, the reader box 102 may generate air pressure to open the opening mechanism 304 and move the dry or lyophilized reagent 312 due to the action of gravity. These are just a few examples of the release of the dry or lyophilized reagent 312 and should not be considered limiting. Any type of release mechanism for the dry or lyophilized reagent 312 should be considered within the scope of this disclosure.
[036] Regardless of how it is released, the dry or lyophilized reagent 312 can move to the test cartridge 120 through port 310. The dry or lyophilized reagent 312 can then move down the chute 308 to reach a reaction chamber and mix with the sample to be amplified. After the release of the dry or lyophilized reagent 312, the rotary dispenser 302 moves one position (as shown, clockwise), so that another loaded chamber 314 aligns with port 310 of the test cartridge 120.
[037] FIGURE 4 shows an example of a spring-loaded dispenser 402 for dispensing a reagent into the test cartridge 120, according to exemplary embodiments of the present disclosure. The spring-loaded dispenser 402 and its interface with the test cartridge 120 are merely an illustration and should not be considered limiting.
[038] The spring-loaded dispenser 402 includes a hollow body 416 where multiple dry or lyophilized reagents 404 are loaded. A spring 406 inside the hollow body 416 provides a drive mechanism to push the reagents. Petition 870250102292, dated 07 / 11 / 2025, page 26 / 44 12 / 19 dry or lyophilized reagent 404 out of the hollow body and into a port 412 of the test cartridge 120. For example, spring 406 provides sufficient force to push a dry or lyophilized reagent 404 out of the hollow chamber when port 412 of the test cartridge 120 aligns with a lower area 414 of the spring-loaded dispenser 402. When a pellet of dry or lyophilized reagent 404 is thus dispensed, spring 406 pushes another dry or lyophilized reagent 404 at the end of the spring-loaded dispenser 402 for another test. The dispensed dry or lyophilized reagent moves down a chute 410 to reach a reaction chamber to perform a step in the NAA amplification process.
[039] FIGURES 5A-5B show an example attachment 502 in test cartridge 120, according to example embodiments of this disclosure. Attachment 502 is attached to test cartridge 120 to create an additional reaction chamber within test cartridge 120 and / or to add additional reagents within test cartridge 120. As with the embodiments above, it should be understood that attachment 502 is shown for illustrative purposes only and should not be considered limiting. In other words, attachments with alternative structures and functionalities should be considered within the scope of this disclosure.
[040] As shown, the attached fitting 502 includes a reagent 504 within its walls. The attached fitting 502 may additionally contain a fungible part 506 which may be punctured and / or otherwise destroyed so that other components of the test cartridge 120 may access the attached fitting 502 when it is attached to the test cartridge 120.
[041] The equivalent section of the test cartridge 120 includes a receiving chamber 510 which is configured to receive the attachment 502. A hatch 508 which rotates within the receiving chamber 510 is provided on the top of the chamber. Petition 870250102292, dated 07 / 11 / 2025, p. 27 / 44 13 / 19 receiver 510. A fluid tube 512 with a drilling member 516 interfaces with the receiver chamber 510.
[042] To attach the attachment 502, the user can press the attachment 502 against the hatch 508, which will in turn rotate inward. After applying additional pressure, the attachment 502 enters the receiving chamber 510. The piercing member 516 pierces the fungible part 506, thus allowing the fluidic tube 512 and the reaction chamber 514 to access the reagent 504 inside the attachment 502. The reagent 504 may include, but is not limited to, dry, lyophilized, or liquid reagent.
[043] Reagent 504 generally includes primers and probes for specific NAA tests. For example, different attachments 502 can be developed for different NAA tests. Therefore, an empty test cartridge 120 (e.g., with magnetic beads but no reagents) can be quickly customized at the time of testing using attachments 502 with primers and probes specific to the desired NAA tests. In some embodiments, the same test cartridge 120 can have multiple receiver chambers 510 for multiple attachments 502. For example, test cartridge 120 can have three attachments 502—with three different types of primers and probes—for three different NAA tests.
[044] The NAA test, as described in this document, differs from other tests by detecting genetic material (RNA or DNA) instead of antigens or antibodies. The detection of genetic material allows for early diagnosis of a disease, as the detection of antigens and / or antibodies often requires time for them to begin appearing in the bloodstream. Because the amount of a certain genetic material is usually very small, many NAAs include a step that amplifies the genetic material and makes many copies of it. These NAAs are also referred to as nucleic acid amplification tests (NAATs). There are several Petition 870250102292, dated 07 / 11 / 2025, p. 28 / 44 14 / 19 Possible amplification techniques foreseen for use in the present invention, including, without limitation, polymerase chain reaction (PCR), strand displacement assay (SDA), or transcription-mediated assay (TMA). The embodiments disclosed herein can be applied to isothermal nucleic acid detection and amplification reactions. Examples for this category of analytical methods are LAMP (loop-mediated isothermal amplification), RPA (recombinase polymerase amplification), tHDA (helix-dependent amplification), NEAR (nicking enzyme amplification reaction), and NASBA (nucleic acid sequence-based amplification).
[045] The methods of the invention are useful for detecting the presence of pathogens (e.g., viral, such as coronavirus, or bacterial) and also for the early detection of cancer or other diseases, for example, through genetic mutations. For example, cancer cells may have specific biomarkers (showing the corresponding genetic mutations) in their nucleic acid materials, which can be amplified by the techniques disclosed in this document. The amplified biomarkers can then be used to detect the specific type of cancer. Some non-limiting examples of cancer include liver cancer, brain cancer, blood cancer, bone cancer, skin cancer and / or any other type of cancer. The nucleic acid used in the device and methods of the invention includes human and non-human (e.g., veterinary) samples.Furthermore, the invention is useful for forensic purposes when the amount of nucleic acid in a sample is less than the detection limits for common tests. It should be understood that DNA, RNA, or both can be detected by the methods of the invention.
[046] Nucleic acids according to this disclosure are not limited and include any nucleic acid. By way of example, and not as a limitation, nucleic acid may be: DNA, including but not limited to genomic DNA, DNA Petition 870250102292, dated 07 / 11 / 2025, p. 29 / 44 15 / 19 mitochondrial DNA, bacterial DNA, viral DNA, plasmids, cosmids, linear oligodeoxynucleotides and polydeoxynucleotides, cDNA, PCR fragments, PCR amplicons, tHDA amplicons, LCR amplicons, long-range PCR amplicons, oligonucleotides, primers, probes, artificial or synthetic DNA; RNA, including, without limitation, mRNA, tRNA, rRNA, viral RNA, siRNA, miRNA, RNAi, linear oligonucleotides, linear polynucleotides, probes, artificial or synthetic RNA; artificial nucleic acids, such as PNA and LNA, as well as combinations thereof, such as nucleic acids comprising DNA and RNA, and hybrids thereof, such as RNA:DNA hybrids; nucleic acid complexes with other biological components. Nucleic acid may be single-stranded or double-stranded.It may contain modifications, such as natural modifications and artificial modifications, and may contain artificial nucleotides comprising, for example, artificial bases, artificial sugar moieties and / or artificial connections between nucleotides.
[047] Nucleic acids may include, without limitation, nucleic acids found in specimens or cultures (e.g., cell, microbial, or microbiological), including biological and environmental samples. Nucleic acids may be found in any biological samples of cell culture, bacteria, viruses, an animal, including human samples, fluids, solids (e.g., feces), or tissue. Target nucleic acids may additionally be found in biological samples, including, without limitation, cervical samples (e.g., a sample obtained from a cervical swab), adenoid cells, skin cells, anal epithelial cells, blood, blood products such as serum, plasma, or buffy coat, saliva, cerebrospinal fluid, pleural fluid, milk, lymph, sputum, urine, and semen.In other forms, the nucleic acids are from other viruses, bacteria, parasites, for example, Herpesviridae, HIV, Chlamydia trachomatis, Neisseria gonorrhoeae spp, Mycobacterium tuberculosis, Coronaviridae and / or influenza.
[048] In one embodiment, the nucleic acids are human papillomavirus Petition 870250102292, dated 07 / 11 / 2025, pp. 30 / 44 16 / 19 (HPV) and include genetic variants of HPV. A variant includes polymorphisms, mutants, derivatives, modified, altered, or other forms of nucleic acid. In one embodiment, the nucleic acid is HPV nucleic acid. In another embodiment, the HPV nucleic acid is HPV DNA and / or RNA from a high-risk HPV type. In yet another embodiment, the nucleic acids are high-risk HPV types such as 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 26, 66, and / or 82.
[049] Samples containing nucleic acid include, but are not limited to, a specimen or culture (e.g., cell, microbiological, and viral cultures), including biological and environmental samples. Biological samples may be from any source, such as cell culture, bacteria, viruses, an animal, including human samples, fluids, solids (e.g., feces) or tissue, as well as liquid and solid food and feed and ingredients, such as dairy products, vegetables, meat and meat by-products, and waste. Environmental samples include, for example, environmental material such as surface matter, soil, water, and industrial samples, as well as samples obtained from instruments, apparatus, equipment, utensils, disposable and non-disposable items for food and dairy processing.Exemplary biological samples include, without limitation, cell samples such as cervical epithelial cells (e.g., a sample obtained from a cervical swab), adenoid cells, anal epithelial cells, blood, blood products such as serum, plasma or buffy coat, saliva, cerebrospinal fluid, pleural fluid, milk, lymph, sputum and semen, and may be collected, for example, in Preservcyt, Surepath and / or Digene Collection Media (DCM). The sample may comprise deoxyribonucleic acid (DNA) and / or ribonucleic acid (RNA).
[050] In some respects, devices and methods can be used to detect the presence or absence of nucleic acids associated with one or more viruses in a biological sample. Non-limiting examples of virus types include double-stranded DNA viruses, single-stranded DNA viruses, double-stranded RNA viruses, or viruses Petition 870250102292, dated 07 / 11 / 2025, page 31 / 44 17 / 19 single-stranded RNA. Single-stranded RNA viruses can replicate directly or can include DNA intermediates in their life cycle. DNA viruses can replicate directly or through RNA intermediates.
[051] In some respects, devices and methods can be used to detect the presence or absence of nucleic acids associated with one or more fungi in a biological sample. Examples of fungal pathogens include, but are not limited to, Aspergillus, Blastomyces, Coccidioides, Cryptococcus, Histoplasma, Paracoccidioides, Sporothrix, Pneumocystis, Candida spp, and Zygomycetes.
[052] In some respects, devices and methods can be used to detect the presence or absence of nucleic acids associated with one or more parasites in a biological sample. Non-limiting examples of parasites include Plasmodium, Leishmania, Babesia, Treponema, Trypanosoma, Toxoplasma gondii, Plasmodium spp., Trypanosoma spp., or bacteria. In other words, the embodiments disclosed herein can be used to detect any type of nucleic acid (e.g., DNA, RNA) from any type of pathogen (e.g., viruses, bacteria, etc.) to detect the various example diseases disclosed herein and / or other diseases.
[053] In some cases, the biological sample may be contained within an environmental sample containing a medium such as water, soil, air, and the like. In some cases, the biological sample may be a forensic sample (e.g., hair, blood, bone, semen, saliva, etc.). In some cases, the biological sample may contain pathogens for bioterrorism attacks (e.g., influenza, anthrax, smallpox).
[054] In some respects, the biological sample comprises an infectious pathogen associated with a Sexually Transmitted Disease (STD) or a Sexually Transmitted Infection (STI). Non-limiting examples of STDs or Petition 870250102292, dated 07 / 11 / 2025, pages 32 / 44 18 / 19 STIs and related infectious pathogens that can be detected using the devices and methods provided in this document may include Bacterial Vaginosis; Chlamydia (Chlamydia trachomatis); Genital Herpes (Herpes Virus); Gonorrhea (Neisseria gonorrhoeae); Hepatitis (e.g., Hepatitis A, B, C, D, E); Genital Warts, Anal Warts, Cervical Cancer (Human Papillomavirus); Lymphogranuloma Venereum (Chlamydia trachomatis); Syphilis (Treponema pallidum); Trichomoniasis (Trichomonas vaginalis); Yeast Infection (Candida spp); and Acquired Immunodeficiency Syndrome (Human Immunodeficiency Virus). and / or Plasmodium spp (e.g., Falciparum, ovale, vivax, etc.).
[055] In one aspect of the invention, the NAA test can be performed in a home environment. The invention offers the advantage of not needing to be employed in a traditional laboratory setting and is therefore useful in facilities such as, for example, correctional facilities, military bases, ships, infirmaries (e.g., military, university), nursing homes, veterinary clinics, zoos, elderly care facilities, small or rural communities, rest homes, or other facilities that might otherwise require the patient to travel to a doctor's office or hospital, for example.
[056] The methods disclosed in this document can be used for NAA quantification methods to detect pathogen load (e.g., viral load, bacterial load) in a sample. In other words, the number of replications can be estimated using statistical techniques and / or counted to determine the initial pathogen load in the biological sample. A higher number of replications may indicate a lower pathogen load in the biological sample, and a lower number of replications may indicate a higher pathogen load in the biological sample.
[057] Additional examples of method and device modalities Petition 870250102292, dated 07 / 11 / 2025, pp. 33 / 44 The 19 / 19 examples currently described are suggested in accordance with the structures and techniques described in this document. Other, non-limiting examples may be configured to operate separately or may be combined in any permutation or combination with any one or more of the other examples provided above or throughout this disclosure.
[058] Those skilled in the art will understand that the present disclosure can be incorporated into other specific forms without departing from the spirit or essential characteristics thereof. The embodiments currently disclosed are therefore considered in all respects to be illustrative and not restrictive. The scope of the disclosure is indicated by the appended claims rather than the previous description, and all changes that are within the meaning, scope and equivalence thereof shall be included therein.
[059] It should be noted that the terms “including” and “comprising” should be interpreted as meaning “including, but not limited to.” Unless explicitly stated in the claims, the term “a” should be interpreted as “at least one,” and “the,” “referred to,” etc. should be interpreted as “the at least one,” “referred to at least one,” etc. Furthermore, it is the Claimant’s intention that only claims that include the phrase “means to” or “step to” be interpreted under 35 U.S.C. 112(f). Claims that do not expressly include the phrase “means to” or “step to” should not be interpreted under 35 U.S.C. 112(f).
[060] Although the invention has been described with reference to the currently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Consequently, the invention is limited only by the following claims. Petition 870250102292, dated 07 / 11 / 2025, pp. 34 / 44
Claims
1 / 4 CLAIMS 1. System for nucleic acid amplification testing, CHARACTERIZED by comprising: a customizable test cartridge comprising a plurality of fluidic chambers interconnected by fluidic tubing, the customizable test cartridge with a primer and a probe and configured to receive a sample to be tested; and a reader box configured to: receive the customizable test cartridge, insert an enzyme or reagent into the customizable test cartridge, and generate a nucleic acid amplification test result on the sample.
2. System according to claim 1, CHARACTERIZED in that the primer and probe are pre-loaded into the customizable test cartridge during the manufacture of the customizable test cartridge.
3. System according to claim 1, CHARACTERIZED in that the primer and probe are attached by snapping into attachments for the customizable test cartridge before its insertion into the reader box.
4. System according to claim 1, CHARACTERIZED by the reader box comprising a spring-loaded enzyme dispenser configured to dispense the enzyme into the customizable test cartridge.
5. System according to claim 1, CHARACTERIZED by the reader box comprising a rotary enzyme dispenser configured to dispense the enzyme into the customizable test cartridge.
6. System according to claim 1, CHARACTERIZED by the reader box comprising a reagent tray configured to be inserted into the customizable test cartridge by means of a pumping mechanism.
7. System according to claim 1, CHARACTERIZED by the primer and probe being configured for a first nucleic acid amplification test, the customizable test cartridge comprising a second primer and a second probe for a second nucleic acid amplification test.
8. System according to claim 1, CHARACTERIZED by the reader box being configured to: receive a second customizable test cartridge, insert a second enzyme or reagent into the customizable test cartridge, and generate a second result of a second nucleic acid amplification test, wherein the nucleic acid amplification test and the second nucleic acid amplification test are performed in parallel.
9. System according to claim 1, CHARACTERIZED by the reader box being configured to insert the enzyme as a pellet or lyophilized reagent into the customizable test cartridge.
10. Customizable cartridge for nucleic acid amplification testing, CHARACTERIZED by comprising: a plurality of fluidic chambers interconnected by fluidic tubing, the customizable test cartridge with a primer and a probe for nucleic acid amplification testing in one of the pluralities of fluidic chambers.
11. Customizable cartridge, according to claim 10, CHARACTERIZED in that the primer and probe are pre-loaded into the customizable test cartridge during the manufacture of the customizable test cartridge.
12. Customizable cartridge, according to claim 10, CHARACTERIZED in that the primer and probe are attached by snapping into attachments for the customizable test cartridge.
13. Customizable cartridge, according to claim 10, CHARACTERIZED by the primer and probe being configured for a first nucleic acid amplification test, the customizable test cartridge comprising a second primer and a second probe configured for a second nucleic acid amplification test.
14. Nucleic acid amplification test method, CHARACTERIZED by comprising: inserting, into a reader box, a customizable test cartridge comprising a plurality of fluidic chambers interconnected by fluidic tubes, the customizable test cartridge with a primer and a probe, in addition to a sample to be tested; inserting, through the reader box, an enzyme or reagent into the customizable test cartridge; and generating, through the reader box, a nucleic acid amplification test result on the sample.
15. Method according to claim 14, CHARACTERIZED in that the primer and probe are pre-loaded into the customizable test cartridge during the manufacture of the customizable test cartridge.
16. Method according to claim 14, CHARACTERIZED by further comprising: attaching the primer and probe by snapping into attachments on the customizable test cartridge before its insertion into the reader box.
17. Method, according to claim 14, CHARACTERIZED by the insertion of the enzyme into the customizable test cartridge comprising: dispensing, by means of a spring-loaded enzyme dispenser in the reader box, the enzyme into the customizable test cartridge.
18. Method, according to claim 14, CHARACTERIZED by the insertion of the enzyme into the customizable test cartridge comprising: dispensing, by a rotating enzyme dispenser in the reader box, the enzyme Petition 870250102292, dated 07 / 11 / 2025, page 37 / 44 4 / 4 into the customizable test cartridge.
19. Method according to claim 14, further characterized by comprising: inserting, through the reader box, one or more reagents from a reagent tray into the customizable test cartridge by means of a pumping mechanism.
20. Method according to claim 14, CHARACTERIZED in that the primer and probe are for a first nucleic acid amplification test, the customizable test cartridge comprising a second primer and a second probe for a second nucleic acid amplification test.
21. Method according to claim 14, CHARACTERIZED in that the sample is a biological sample.
22. Method according to claim 14, CHARACTERIZED in that the nucleic acid is a human or microbial nucleic acid.
23. Method according to claim 22, CHARACTERIZED in that the microbial nucleic acid is a bacterial, parasitic or viral nucleic acid. Petition 870250102292, dated 07 / 11 / 2025, pp. 38 / 44
